Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Where Are The Biosimilars?

This article was originally published in RPM Report

Executive Summary

An abbreviated pathway for follow-on biologics was one of the biggest issues for biotech investors in the legislative debate over health care reform. Two years after enactment, FDA is still waiting for the first application.


Related Content

Words Of Wisdom For Biosimilar Developers
Biosimilars: Is The Game About To Change In Europe?
Much “Ado” About Biosimilars
No Comparison: FDA Draws Bright Line Between BLA, Biosimilar Pathways In Tbo-filgrastim Review
Biopharmaceutical Trends In 2012: Regulatory And Market Strides Paper Over Existential Dilemmas
Biosimilarity vs. “Cognitive Dissonance”: The Ongoing Challenges to New FDA Pathway
Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain
Biosimilars: Inverting the Innovator Development Model
Biosimilars Pathway Dilemma: When Should Sponsors Pick (k) Before (a)?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts